{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:05:41Z","timestamp":1782187541755,"version":"3.54.5"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100017700","name":"Henan Provincial Science and Technology Research Project","doi-asserted-by":"publisher","award":["SBGJ202102035"],"award-info":[{"award-number":["SBGJ202102035"]}],"id":[{"id":"10.13039\/501100017700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dopamine dysregulation syndrome (DDS) is a complication of Parkinson\u2019s disease (PD) that seriously affects the quality of life of PD patients. Currently, the risk factors for DDS are poorly known, and it is critical to identify them in the early stages of PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To explore the incidence of and risk factors for DDS in patients with early PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted on the general data, clinical features, and imaging data of patients with early PD in the PPMI database. Multivariate Cox regression analysis was performed to analyze the risk factors for the development of DDS in patients with early PD, and Kaplan\u2012Meier curves examined the frequency and predictors of incident DDS symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At baseline, 2.2% (\n                      <jats:italic>n<\/jats:italic>\n                      = 6) of patients with early PD developed DDS, and the cumulative incidence rates of DDS during the 5-year follow-up period were 2.8%, 6.4%, 10.8%, 15.5%, and 18.7%, respectively. In the multivariate Cox regression model controlling for age, sex, and drug use, hypersexuality (HR = 3.088; 95% CI: 1.416~6.732;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.005), compulsive eating (HR = 3.299; 95% CI: 1.665~6.534;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.001), compulsive shopping (HR = 3.899; 95% CI: 1.769~8.593;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.001), anxiety (HR = 4.018; 95% CI: 2.136~7.599;\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.01), and lower Hoehn-Yahr (H-Y) stage (HR = 0.278; 95% CI: 0.152~0.509;\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.01) were independent risk factors for DDS in patients with early PD. PD patients with DDS had lower DAT uptake values than those patients without DDS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Early PD patients with hypersexuality, compulsive eating, compulsive shopping, anxiety, and lower H-Y stage were at increased risk for DDS. The occurrence of DDS may be related to the decrease in the average DAT uptake of the caudate and putamen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10072-023-06956-w","type":"journal-article","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T18:01:41Z","timestamp":1689357701000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Predictors of dopamine dysregulation syndrome in patients with early Parkinson\u2019s disease"],"prefix":"10.1007","author":[{"given":"Keke","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5825-1927","authenticated-orcid":false,"given":"Jianjun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dashuai","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanze","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linrui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"GU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,14]]},"reference":[{"issue":"10291","key":"6956_CR1","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C (2021) Parkinson\u2019s disease. Lancet (London, England) 397(10291):2284\u20132303","journal-title":"Lancet (London, England)"},{"issue":"5","key":"6956_CR2","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","volume":"20","author":"E Tolosa","year":"2021","unstructured":"Tolosa E, Garrido A, Scholz SW, Poewe W (2021) Challenges in the diagnosis of Parkinson\u2019s disease. The Lancet Neurol 20(5):385\u2013397","journal-title":"The Lancet Neurol"},{"issue":"2","key":"6956_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.mcna.2018.10.014","volume":"103","author":"SG Reich","year":"2019","unstructured":"Reich SG, Savitt JM (2019) Parkinson\u2019s Disease. Med Clin North Am 103(2):337\u2013350","journal-title":"Med Clin North Am"},{"issue":"4","key":"6956_CR4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/jnnp.68.4.423","volume":"68","author":"G Giovannoni","year":"2000","unstructured":"Giovannoni G, O\u2019Sullivan JD, Turner K, Manson AJ, Lees AJ (2000) Hedonistic homeostatic dysregulation in patients with Parkinson\u2019s disease on dopamine replacement therapies. J Neurol, Neurosurg, Psychiatry 68(4):423\u2013428","journal-title":"J Neurol, Neurosurg, Psychiatry"},{"key":"6956_CR5","doi-asserted-by":"publisher","first-page":"731552","DOI":"10.3389\/fneur.2021.731552","volume":"12","author":"T Xu","year":"2021","unstructured":"Xu T, Cao L, Long W, Zhao G (2021) Validation of the Chinese version of the questionnaire for impulsive-compulsive disorders in Parkinson\u2019s disease. Front Neurol 12:731552","journal-title":"Front Neurol"},{"issue":"2","key":"6956_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/mdc3.13122","volume":"8","author":"C Rodriguez-Blazquez","year":"2021","unstructured":"Rodriguez-Blazquez C, Schrag A, Rizos A, Chaudhuri KR, Martinez-Martin P, Weintraub D (2021) Prevalence of Non-motor symptoms and non-motor fluctuations in Parkinson\u2019s disease using the MDS-NMS. Mov Disord Clin Pract 8(2):231\u2013239","journal-title":"Mov Disord Clin Pract"},{"issue":"2","key":"6956_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2165\/00023210-200923020-00005","volume":"23","author":"SS O'Sullivan","year":"2009","unstructured":"O\u2019Sullivan SS, Evans AH, Lees AJ (2009) Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS drugs 23(2):157\u2013170","journal-title":"CNS drugs"},{"issue":"2","key":"6956_CR8","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/psyg.12489","volume":"20","author":"A Gulunay","year":"2020","unstructured":"Gulunay A, Cakmakli GY, Yon MI, Ulusoy EK, Karakoc M (2020) Frequency of non-motor symptoms and their impact on the quality of life in patients with Parkinson\u2019s disease: a prospective descriptive case series. Psychogeriatrics 20(2):206\u2013211","journal-title":"Psychogeriatrics"},{"issue":"1\u20132","key":"6956_CR9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jns.2013.05.013","volume":"331","author":"K Tanaka","year":"2013","unstructured":"Tanaka K, Wada-Isoe K, Nakashita S, Yamamoto M, Nakashima K (2013) Impulsive compulsive behaviors in Japanese Parkinson\u2019s disease patients and utility of the Japanese version of the questionnaire for impulsive-compulsive disorders in Parkinson\u2019s disease. J Neurol Sci 331(1\u20132):76\u201380","journal-title":"J Neurol Sci"},{"issue":"12","key":"6956_CR10","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1136\/jnnp-2017-315985","volume":"88","author":"N Warren","year":"2017","unstructured":"Warren N, O\u2019Gorman C, Lehn A, Siskind D (2017) Dopamine dysregulation syndrome in Parkinson\u2019s disease: a systematic review of published cases. J Neurol, Neurosurg, Psychiatry 88(12):1060\u20131064","journal-title":"J Neurol, Neurosurg, Psychiatry"},{"issue":"10","key":"6956_CR11","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1212\/01.wnl.0000184487.72289.f0","volume":"65","author":"AH Evans","year":"2005","unstructured":"Evans AH, Lawrence AD, Potts J, Appel S, Lees AJ (2005) Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 65(10):1570\u20131574","journal-title":"Neurology"},{"issue":"3","key":"6956_CR12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/jnnp-2012-303988","volume":"85","author":"R Cilia","year":"2014","unstructured":"Cilia R, Siri C, Canesi M, Zecchinelli AL, De Gaspari D, Natuzzi F, Tesei S, Meucci N, Mariani CB, Sacilotto G, Zini M, Ruffmann C, Pezzoli G (2014) Dopamine dysregulation syndrome in Parkinson\u2019s disease: from clinical and neuropsychological characterisation to management and long-term outcome. J Neurol, Neurosurg Psychiatry 85(3):311\u2013318","journal-title":"J Neurol, Neurosurg Psychiatry"},{"issue":"4","key":"6956_CR13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.pneurobio.2011.09.005","volume":"95","author":"Parkinson Progression Marker Initiative","year":"2011","unstructured":"Parkinson Progression Marker Initiative (2011) The Parkinson progression marker initiative (PPMI). Progress Neurobiol 95(4):629\u2013635","journal-title":"Progress Neurobiol"},{"issue":"1","key":"6956_CR14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(16)30328-3","volume":"16","author":"A Schrag","year":"2017","unstructured":"Schrag A, Siddiqui UF, Anastasiou Z, Weintraub D, Schott JM (2017) Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson\u2019s disease: a cohort study. The Lancet Neurol 16(1):66\u201375","journal-title":"The Lancet Neurol"},{"issue":"15","key":"6956_CR15","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N (2008) Movement disorder society-sponsored revision of the Unified Parkinson\u2019s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23(15):2129\u20132170","journal-title":"Mov Disord"},{"issue":"19","key":"6956_CR16","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1212\/WNL.0b013e3181fc29c9","volume":"75","author":"JC Dalrymple-Alford","year":"2010","unstructured":"Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livingston L, Graham C, Crucian GP, Melzer TR, Kirwan J, Keenan R, Wells S, Porter RJ, Watts R, Anderson TJ (2010) The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 75(19):1717\u20131725","journal-title":"Neurology"},{"issue":"12","key":"6956_CR17","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1212\/WNL.0000000000000801","volume":"83","author":"P de la Riva","year":"2014","unstructured":"de la Riva P, Smith K, Xie SX, Weintraub D (2014) Course of psychiatric symptoms and global cognition in early Parkinson disease. Neurology 83(12):1096\u20131103","journal-title":"Neurology"},{"issue":"9","key":"6956_CR18","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/mds.20213","volume":"19","author":"CG Goetz","year":"2004","unstructured":"Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, Giladi N, Holloway RG, Moore CG, Wenning GK, Yahr MD, Seidl L (2004) Movement disorder society task force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 19(9):1020\u20131028","journal-title":"Mov Disord"},{"issue":"5","key":"6956_CR19","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/mdc3.12671","volume":"5","author":"P Barbosa","year":"2018","unstructured":"Barbosa P, Djamshidian A, Lees AJ, Warner TT (2018) The outcome of dopamine dysregulation syndrome in Parkinson\u2019s disease: a retrospective postmortem study. Mov Disord Clin Pract 5(5):519\u2013522","journal-title":"Mov Disord Clin Pract"},{"issue":"4","key":"6956_CR20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.neurol.2018.07.009","volume":"175","author":"H El Otmani","year":"2019","unstructured":"El Otmani H, Mouni FZ, Abdulhakeem Z, Attar Z, Rashad L, Saali I, El Moutawakil B, Rafai MA, Slassi I, Nadifi S (2019) Impulse control disorders in Parkinson disease: a cross-sectional study in Morocco. Revue Neurologique 175(4):233\u2013237","journal-title":"Revue Neurologique"},{"key":"6956_CR21","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.parkreldis.2017.02.024","volume":"38","author":"T Maeda","year":"2017","unstructured":"Maeda T, Shimo Y, Chiu SW, Yamaguchi T, Kashihara K, Tsuboi Y, Nomoto M, Hattori N, Watanabe H, Saiki H (2017) Clinical manifestations of nonmotor symptoms in 1021 Japanese Parkinson\u2019s disease patients from 35 medical centers. Parkinsonism Relat Disord 38:54\u201360","journal-title":"Parkinsonism Relat Disord"},{"issue":"10","key":"6956_CR22","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/j.clineuro.2013.07.014","volume":"115","author":"ST Tsai","year":"2013","unstructured":"Tsai ST, Hung HY, Hsieh TC, Lin SH, Lin SZ, Chen SY (2013) Long-term outcome of young onset Parkinson\u2019s disease after subthalamic stimulation\u2013a cross-sectional study. Clin Neurol Neurosurg 115(10):2082\u20132087","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"6956_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1176\/appi.ajp.2018.18040465","volume":"176","author":"D Weintraub","year":"2019","unstructured":"Weintraub D, Mamikonyan E (2019) Impulse control disorders in Parkinson\u2019s disease. Am J Psychiatry 176(1):5\u201311","journal-title":"Am J Psychiatry"},{"key":"6956_CR24","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev.ps.40.020189.001203","volume":"40","author":"RA Wise","year":"1989","unstructured":"Wise RA, Rompre PP (1989) Brain dopamine and reward. Annu Rev Psychol 40:191\u2013225","journal-title":"Annu Rev Psychol"},{"issue":"3","key":"6956_CR25","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.psychres.2014.12.005","volume":"225","author":"P Tanwani","year":"2015","unstructured":"Tanwani P, Fernie BA, Nik\u010devi\u0107 AV, Spada MM (2015) A systematic review of treatments for impulse control disorders and related behaviours in Parkinson\u2019s disease. Psychiatry Res 225(3):402\u2013406","journal-title":"Psychiatry Res"},{"issue":"11","key":"6956_CR26","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1002\/mds.22505","volume":"24","author":"AH Evans","year":"2009","unstructured":"Evans AH, Strafella AP, Weintraub D, Stacy M (2009) Impulsive and compulsive behaviors in Parkinson\u2019s disease. Mov Disord 24(11):1561\u20131570","journal-title":"Mov Disord"},{"issue":"5\u20136","key":"6956_CR27","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/FBP.0b013e32833109a0","volume":"20","author":"S Fenu","year":"2009","unstructured":"Fenu S, Wardas J, Morelli M (2009) Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson\u2019s disease. Behav Pharmacol 20(5\u20136):363\u2013379","journal-title":"Behav Pharmacol"},{"issue":"3","key":"6956_CR28","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.neubiorev.2010.06.007","volume":"35","author":"KL Eskow Jaunarajs","year":"2011","unstructured":"Eskow Jaunarajs KL, Angoa-Perez M, Kuhn DM, Bishop C (2011) Potential mechanisms underlying anxiety and depression in Parkinson\u2019s disease: consequences of l-DOPA treatment. Neurosci Biobehav Rev 35(3):556\u2013564","journal-title":"Neurosci Biobehav Rev"},{"issue":"4","key":"6956_CR29","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/archneur.1969.00480160015001","volume":"21","author":"MD Yahr","year":"1969","unstructured":"Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM (1969) Treatment of parkinsonism with levodopa. Arch Neurol 21(4):343\u2013354","journal-title":"Arch Neurol"},{"issue":"1\u20132","key":"6956_CR30","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jns.2009.07.026","volume":"287","author":"HJ Kim","year":"2009","unstructured":"Kim HJ, Park SY, Cho YJ, Hong KS, Cho JY, Seo SY, Lee DH, Jeon BS (2009) Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment. J Neurol Sci 287(1\u20132):200\u2013204","journal-title":"J Neurol Sci"},{"issue":"1","key":"6956_CR31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S0022-510X(99)00198-7","volume":"172","author":"C Choi","year":"2000","unstructured":"Choi C, Sohn YH, Lee JH, Kim J (2000) The effect of long-term levodopa therapy on depression level in de novo patients with Parkinson\u2019s disease. J Neurol Sci 172(1):12\u201316","journal-title":"J Neurol Sci"},{"issue":"7","key":"6956_CR32","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/FBP.0b013e32833e7e80","volume":"21","author":"KL Eskow Jaunarajs","year":"2010","unstructured":"Eskow Jaunarajs KL, Dupre KB, Ostock CY, Button T, Deak T, Bishop C (2010) Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat. Behav Pharmacol 21(7):627\u2013637","journal-title":"Behav Pharmacol"},{"issue":"1","key":"6956_CR33","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.nbd.2010.01.012","volume":"38","author":"S Navailles","year":"2010","unstructured":"Navailles S, Bioulac B, Gross C, De Deurwaerd\u00e8re P (2010) Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson\u2019s disease. Neurobiol Dis 38(1):136\u2013143","journal-title":"Neurobiol Dis"},{"issue":"10","key":"6956_CR34","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.biopsych.2004.07.007","volume":"56","author":"ND Volkow","year":"2004","unstructured":"Volkow ND (2004) The reality of comorbidity: depression and drug abuse. Biol Psychiatry 56(10):714\u2013717","journal-title":"Biol Psychiatry"},{"issue":"6","key":"6956_CR35","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1590\/0004-282x20180052","volume":"76","author":"AP Vargas","year":"2018","unstructured":"Vargas AP, Cardoso FEC (2018) Impulse control and related disorders in Parkinson\u2019s disease. Arq de Neuro-Psiquiatr 76(6):399\u2013410","journal-title":"Arq de Neuro-Psiquiatr"},{"issue":"12","key":"6956_CR36","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/mds.22652","volume":"24","author":"W Gerschlager","year":"2009","unstructured":"Gerschlager W, Bloem BR (2009) Managing pathological gambling in Parkinson\u2019s disease with enteral levodopa\/carbidopa infusions. Mov Disord 24(12):1858\u20131860","journal-title":"Mov Disord"},{"issue":"1","key":"6956_CR37","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/mds.870060107","volume":"6","author":"P Giovannini","year":"1991","unstructured":"Giovannini P, Piccolo I, Genitrini S, Soliveri P, Girotti F, Geminiani G, Scigliano G, Caraceni T (1991) Early-onset Parkinson\u2019s disease. Mov Disord 6(1):36\u201342","journal-title":"Mov Disord"},{"issue":"6","key":"6956_CR38","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1176\/appi.ajp.160.6.1041","volume":"160","author":"RA Chambers","year":"2003","unstructured":"Chambers RA, Taylor JR, Potenza MN (2003) Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability. Am J Psychiatry 160(6):1041\u20131052","journal-title":"Am J Psychiatry"},{"issue":"7","key":"6956_CR39","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1002\/mds.25886","volume":"29","author":"C Vriend","year":"2014","unstructured":"Vriend C, Nordbeck AH, Booij J, van der Werf YD, Pattij T, Voorn P, Raijmakers P, Foncke EM, van de Giessen E, Berendse HW, van den Heuvel OA (2014) Reduced dopamine transporter binding predates impulse control disorders in Parkinson\u2019s disease. Mov Disord 29(7):904\u2013911","journal-title":"Mov Disord"},{"issue":"8","key":"6956_CR40","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1136\/jnnp-2015-311827","volume":"87","author":"KM Smith","year":"2016","unstructured":"Smith KM, Xie SX, Weintraub D (2016) Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease. J Neurol, Neurosurg, Psychiatry 87(8):864\u2013870","journal-title":"J Neurol, Neurosurg, Psychiatry"},{"issue":"1","key":"6956_CR41","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.nbd.2010.03.013","volume":"39","author":"R Cilia","year":"2010","unstructured":"Cilia R, Ko JH, Cho SS, van Eimeren T, Marotta G, Pellecchia G, Pezzoli G, Antonini A, Strafella AP (2010) Reduced dopamine transporter density in the ventral striatum of patients with Parkinson\u2019s disease and pathological gambling. Neurobiol Dis 39(1):98\u2013104","journal-title":"Neurobiol Dis"},{"issue":"2","key":"6956_CR42","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1136\/jnnp-2013-305395","volume":"85","author":"V Voon","year":"2014","unstructured":"Voon V, Rizos A, Chakravartty R, Mulholland N, Robinson S, Howell NA, Harrison N, Vivian G, Ray Chaudhuri K (2014) Impulse control disorders in Parkinson\u2019s disease: decreased striatal dopamine transporter levels. J Neurol, Neurosurg, Psychiatry 85(2):148\u2013152","journal-title":"J Neurol, Neurosurg, Psychiatry"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-06956-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-023-06956-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-06956-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T05:46:13Z","timestamp":1710913573000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-023-06956-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,14]]},"references-count":42,"alternative-id":["6956"],"URL":"https:\/\/doi.org\/10.1007\/s10072-023-06956-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2359730\/v1","asserted-by":"object"}]},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,14]]},"assertion":[{"value":"18 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research protocol was approved by the Ethics Committee of Henan Provincial People\u2019s Hospital. Each site participating in the PPMI was approved by the Ethics Standards Committee for Human Experimentation before the start of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All subjects signed an informed consent form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}